Travere CEO Eric Dube to step down after transforming the rare disease biotech

Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will step down to “focus on his health and family.” Bradley Campbell, formerly CEO of Amicus Therapeutics, will take the reins.